Prosensa Announces Intent to Voluntarily Delist From NASDAQ
30. Januar 2015 08:30 ET
|
Prosensa Holding N.V.
LEIDEN, The Netherlands, Jan. 30, 2015 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (Nasdaq:RNA) ("Prosensa" or the "Company"), the biopharmaceutical company focusing on RNA-modulating therapeutics for...
Prosensa Announces Shareholder Approval of Certain Matters Relating to the BioMarin Tender Offer
13. Januar 2015 08:41 ET
|
Prosensa Holding N.V.
Leiden, The Netherlands, Jan. 13, 2015 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA), the biopharmaceutical
company focusing on RNA-modulating therapeutics for rare diseases
with high unmet...
Prosensa Wins Scrip 'Biotech Company of the Year' 2014 Award
08. Dezember 2014 08:00 ET
|
Prosensa Holding N.V.
Leiden, The Netherlands, Dec. 8, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA), the biopharmaceutical
company focusing on RNA-modulating therapeutics for rare diseases
with a high unmet...
Prosensa Announces 3rd Quarter 2014 Financial Results and Recent Corporate Developments
17. November 2014 07:00 ET
|
Prosensa Holding N.V.
Rolling NDA submission drisapersen underway
EMA filing for conditional approval anticipated to follow NDA submission
Re-dosing has commenced in United States, Belgium &...
Prosensa Holding N.V. to Webcast Conference Call Discussing 3rd Quarter 2014 Financial Results and Corporate Update on November 17, 2014
10. November 2014 08:00 ET
|
Prosensa Holding N.V.
Leiden, The Netherlands, Nov. 10, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA) today
announced that the Company will host a conference call and live
audio webcast on Monday,...
Prosensa to Present at Upcoming Investor Conferences
07. November 2014 10:56 ET
|
Prosensa Holding N.V.
Leiden, The Netherlands, Nov. 7, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA) today announced that Hans
Schikan, Chief Executive Officer, will present a corporate overview
at the...
Prosensa begins NDA submission to the FDA for exon-skipping drug drisapersen to treat Duchenne muscular dystrophy
10. Oktober 2014 10:10 ET
|
Prosensa Holding N.V.
Leiden, The Netherlands, Oct. 10, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA), the biopharmaceutical
company focusing on RNA-modulating therapeutics for rare diseases
with high unmet...
Prosensa extends the re-dosing of drisapersen in Europe in patients with Duchenne muscular dystrophy
26. September 2014 08:00 ET
|
Prosensa Holding N.V.
Leiden, The Netherlands, Sept. 26, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA), the biopharmaceutical
company focusing on RNA-modulating therapeutics for rare diseases
with high unmet...
Prosensa to Present at Upcoming Conferences
25. September 2014 08:00 ET
|
Prosensa Holding N.V.
Leiden, The Netherlands, Sept. 25, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA) today announced that Hans
Schikan, Chief Executive Officer, will present a corporate overview
at the...
Prosensa publishes a sensitive, reproducible and objective methodology for dystrophin analysis in patients with Duchenne muscular dystrophy
24. September 2014 08:00 ET
|
Prosensa Holding N.V.
Leiden, The Netherlands, Sept. 24, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA), the
biopharmaceutical company focusing on RNA-modulating therapeutics
for rare diseases with high unmet...